Boston, Massachusetts
Phase 1 colorectal cancer trials in Boston, MA
54 Phase 1 colorectal cancer studies are recruiting participants at sites in Boston as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Boston at a glance
- 54 studies are recruiting at a site in Boston.
- By phase: Early Phase 1 (2), Phase 1 (27), Phase 1/2 (25).
- By sponsor: industry (45), university, hospital or other (9).
- Most recent update to one of these records: November 17, 2026.
Studies recruiting in Boston
Basic details from each study's public record (the 30 most recently updated of 54). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05786924 · updated
A Phase 1/2 Study of IAM1363 in HER2 Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study sites
- Dana Farber Cancer Institute · Massachusetts General Hospital
- Registry record
- NCT06253871 · updated
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06324357 · updated
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 to 99
- All sexes
- Sponsor
- Erasca, Inc.
- Study sites
- Dana Farber Cancer Institute · Massachusetts General Hospital (MG)
- Registry record
- NCT06983743 · updated
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kestrel Therapeutics, Inc.
- Study site
- Mass General Brigham Cancer Institute at Massachusetts General Hospital
- Registry record
- NCT07458347 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Massachusetts General Hospital
- Registry record
- NCT07020221 · updated
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT07114601 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Massachusetts General Hospital
- Registry record
- NCT07213791 · updated
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- Dana Farber Cancer Institute
- Registry record
- NCT06720987 · updated
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- Massachusetts General Hospital
- Registry record
- NCT07542704 · updated
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Immunome, Inc.
- Study site
- Massachusetts General Hospital
- Registry record
- NCT07578571 · updated
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study sites
- Dana Farber Cancer Institute · Massachusetts General Hospital
- Registry record
- NCT07584226 · updated
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- Massachusetts General Hospital - Dana Farber
- Registry record
- NCT03526835 · updated
First-in-human Study of 7MW4911 in GI Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Study site
- Massachusetts General Hospital
- Registry record
- NCT07216560 · updated
LYL273 for Patients With Relapsed or Refractory mCRC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT05319314 · updated
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Alterome Therapeutics, Inc.
- Registry record
- NCT06835569 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study site
- Dana Farber Cancer Institute
- Registry record
- NCT04657068 · updated
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
- Study site
- Massachusetts General Hospital
- Registry record
- NCT06239194 · updated
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kura Oncology, Inc.
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT06026410 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study sites
- Dana Farber Cancer Institute · Massachusetts General Hospital
- Registry record
- NCT05919264 · updated
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Bicara Therapeutics
- Study site
- Dana Farber/Partners Cancer Care Inc
- Registry record
- NCT04429542 · updated
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Dispatch Biotherapeutics
- Study site
- Dana-Farber Cancer Institute
- Registry record
- NCT07544589 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study sites
- Dana Farber Cancer Institute · Massachusetts General Hospital
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #7
- Registry record
- NCT05176483 · updated
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Study sites
- Dana-Farber Cancer Insitute · Massachusetts General Hospital
- Registry record
- NCT06625775 · updated
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT05877599 · updated
A Study of PHN-012 in Patients With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pheon Therapeutics
- Study site
- PHN-012-001 Site
- Registry record
- NCT07127874 · updated
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Neonc Technologies, Inc.
- Study site
- Tufts Medical Center
- Registry record
- NCT06047379 · updated
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Dana Farber Cancer Institute
- Registry record
- NCT06128551 · updated
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study sites
- Dana Farber Cancer Institute · Massachusetts General Hospital
- Registry record
- NCT06445062 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Boston, MA on ClinicalTrials.gov.
Ask about studies near Boston
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections